Novo Nordisk executive Mike Doustdar stated the growing obesity market is not a zero-sum game against Eli Lilly.
He believes investors underestimate the potential for differentiation among new treatments like oral options. Doustdar expects a segmented market with multiple successful players rather than a simple duopoly.
He compared the future landscape to the beverage industry with choices like Coke, Pepsi, Fanta, and Dr Pepper.
The GLP-1 market should exceed $100 billion by 2030.
Novo Nordisk produces Wegovy and faces competition from Eli Lilly’s Zepbound.